Track topics on Twitter Track topics that are important to you
Novartis expects to submit 50 new drug applications in China between 2019 and 2023 -- ten per year -- according to John Tsai, head of global drug development and chief medical officer for Novartis. The new drugs will target major diseases in China, he said, as he praised China's greatly speeded up regulatory reviews, which now offer timelines similar to the US and EU. "In light of the governmental regulatory reforms, we are working to have every pivotal drug development program include China from the beginning by default," said Tsai. More details....
Stock Symbol: (NYSE: NVS)
Share this with colleagues:
Original Article: Novartis Plans to File 50 NDAs in China over the Next Five YearsNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...